JP2022542450A5 - - Google Patents
Info
- Publication number
- JP2022542450A5 JP2022542450A5 JP2022506483A JP2022506483A JP2022542450A5 JP 2022542450 A5 JP2022542450 A5 JP 2022542450A5 JP 2022506483 A JP2022506483 A JP 2022506483A JP 2022506483 A JP2022506483 A JP 2022506483A JP 2022542450 A5 JP2022542450 A5 JP 2022542450A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- amino acid
- variable region
- chain variable
- acid sequence
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2025047199A JP2025102836A (ja) | 2019-08-02 | 2025-03-21 | 抗ctla4/抗pd-1二重特異性抗体及びその使用 |
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201910711122.4 | 2019-08-02 | ||
| CN201910711122 | 2019-08-02 | ||
| CN201911224135.5 | 2019-12-02 | ||
| CN201911224135 | 2019-12-02 | ||
| PCT/CN2020/106309 WO2021023117A1 (zh) | 2019-08-02 | 2020-07-31 | 抗ctla4-抗pd-1双特异性抗体及其用途 |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025047199A Division JP2025102836A (ja) | 2019-08-02 | 2025-03-21 | 抗ctla4/抗pd-1二重特異性抗体及びその使用 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2022542450A JP2022542450A (ja) | 2022-10-03 |
| JP2022542450A5 true JP2022542450A5 (cg-RX-API-DMAC7.html) | 2023-07-28 |
| JP7655896B2 JP7655896B2 (ja) | 2025-04-02 |
Family
ID=74483591
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022506483A Active JP7655896B2 (ja) | 2019-08-02 | 2020-07-31 | 抗ctla4/抗pd-1二重特異性抗体及びその使用 |
| JP2025047199A Pending JP2025102836A (ja) | 2019-08-02 | 2025-03-21 | 抗ctla4/抗pd-1二重特異性抗体及びその使用 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025047199A Pending JP2025102836A (ja) | 2019-08-02 | 2025-03-21 | 抗ctla4/抗pd-1二重特異性抗体及びその使用 |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20220275089A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP4008730A4 (cg-RX-API-DMAC7.html) |
| JP (2) | JP7655896B2 (cg-RX-API-DMAC7.html) |
| KR (1) | KR20220053578A (cg-RX-API-DMAC7.html) |
| CN (2) | CN122502501A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2020325350A1 (cg-RX-API-DMAC7.html) |
| BR (1) | BR112022002013A2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3146780A1 (cg-RX-API-DMAC7.html) |
| IL (2) | IL321822A (cg-RX-API-DMAC7.html) |
| MX (1) | MX2022001321A (cg-RX-API-DMAC7.html) |
| PH (1) | PH12022550243A1 (cg-RX-API-DMAC7.html) |
| WO (1) | WO2021023117A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN106967172B (zh) | 2016-08-23 | 2019-01-08 | 康方药业有限公司 | 抗ctla4-抗pd-1 双功能抗体、其药物组合物及其用途 |
| CN109053895B (zh) | 2018-08-30 | 2020-06-09 | 中山康方生物医药有限公司 | 抗pd-1-抗vegfa的双功能抗体、其药物组合物及其用途 |
| BR112022002028A2 (pt) * | 2019-08-02 | 2022-04-12 | Cttq Akeso Shanghai Biomed Tech Co Ltd | Anticorpo anti-pd-1 e uso farmacêutico do mesmo |
| EP4008730A4 (en) * | 2019-08-02 | 2023-09-06 | Akeso Pharmaceuticals, Inc. | BISPECIFIC ANTI-CTLA4-ANTI-PD-1 ANTIBODY AND ITS USES |
| JP2023515675A (ja) * | 2020-03-05 | 2023-04-13 | メルク・シャープ・アンド・ドーム・エルエルシー | Pd-1アンタゴニスト、ctla4アンタゴニストおよびレンバチニブまたはその薬学的に許容される塩の組合せを用いる癌を治療する方法 |
| CN118530342A (zh) * | 2021-03-12 | 2024-08-23 | 中山康方生物医药有限公司 | 降低免疫细胞分泌il-8和/或il-6的水平的方法 |
| AU2022233411A1 (en) * | 2021-03-12 | 2023-09-14 | Akeso Biopharma, Inc. | Pharmaceutical combination containing anti-pd-1-anti-vegfa bispecific antibody, and use thereof |
| WO2022218384A1 (zh) * | 2021-04-14 | 2022-10-20 | 中山康方生物医药有限公司 | 抗cd47的单克隆抗体及其用途 |
| IL307494A (en) * | 2021-04-14 | 2023-12-01 | Akeso Pharmaceuticals Inc | Use of antibody in anti-tumor treatment |
| US20240352153A1 (en) * | 2021-07-23 | 2024-10-24 | Akeso Biopharma, Inc | Pharmaceutical composition and use |
| KR20240153590A (ko) * | 2022-02-24 | 2024-10-23 | 아케소 파마슈티컬스, 인코포레이티드 | 항-ctla4-항-pd-1 이중특이적 항체 및 치아우라닙을 포함하는 약제학적 조성물 |
| IL315307A (en) * | 2022-03-07 | 2024-10-01 | Medimmune Llc | Treatment methods using CTLA-4 and PD-1 bispecific antibodies |
| CN118946366A (zh) * | 2022-04-13 | 2024-11-12 | 齐鲁制药有限公司 | 包含抗ctla4和抗pd1的混合抗体的药物组合物及其治疗用途 |
| US20240117051A1 (en) | 2022-09-09 | 2024-04-11 | Akeso Biopharma, Inc. | Therapeutic combination and use thereof |
| US12030945B2 (en) | 2022-10-25 | 2024-07-09 | Seismic Therapeutic, Inc. | Variant IgG Fc polypeptides and uses thereof |
| CN118272524A (zh) * | 2022-12-30 | 2024-07-02 | 康方药业有限公司 | Cd74的医药用途 |
| EP4678186A1 (en) * | 2023-03-07 | 2026-01-14 | Akeso Pharma Co., Ltd. | Pharmaceutical composition comprising anti-ctla4-anti-pd-1 bispecific antibody and use thereof |
| WO2024199435A1 (zh) * | 2023-03-31 | 2024-10-03 | 上海细胞治疗集团股份有限公司 | 双特异性抗体及自分泌双特异性抗体的工程化免疫细胞 |
| CN118767127A (zh) * | 2023-04-10 | 2024-10-15 | 康方药业有限公司 | 抗ctla4-抗pd-1双特异性抗体的医药用途 |
| CN120361206A (zh) * | 2024-01-25 | 2025-07-25 | 中山康方生物医药有限公司 | 抗pd-1-抗vegfa的双特异性抗体的医药用途 |
| WO2025201450A1 (zh) * | 2024-03-27 | 2025-10-02 | 康方汇科(上海)生物有限公司 | 药物组合及用途 |
| WO2025232896A1 (zh) * | 2024-05-10 | 2025-11-13 | 康方汇科(上海)生物有限公司 | 药物组合及用途 |
| CN120965861B (zh) * | 2025-10-22 | 2026-02-13 | 杭州博茵生物技术有限公司 | 一种Fc效应消除的新型骨架流式抗体及其制备方法与应用 |
Family Cites Families (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| KR100600550B1 (ko) | 2000-10-20 | 2006-07-13 | 에자이 가부시키가이샤 | 질소 함유 방향환 유도체 |
| HUE025742T2 (hu) | 2003-12-25 | 2016-04-28 | Eisai R&D Man Co Ltd | 4-(3-klór-4-(ciklopropilamino-karbonil)aminofenoxi)-7-metoxi-6-kinolin-karboxamid vagy szolvátja sójának kristálya és eljárás elõállításukra |
| EP3342782B1 (en) * | 2004-07-15 | 2022-08-17 | Xencor, Inc. | Optimized fc variants |
| US8148532B2 (en) | 2007-03-14 | 2012-04-03 | Guoqing Paul Chen | Spiro substituted compounds as angiogenesis inhibitors |
| EA201500417A1 (ru) * | 2008-08-25 | 2015-11-30 | Эмплиммьюн, Инк. | Композиции антагонистов pd-1 и способы применения |
| CN102711810B (zh) * | 2009-11-30 | 2015-04-22 | 詹森生物科技公司 | 效应子功能已消除的抗体Fc区突变体 |
| US20130089554A1 (en) * | 2009-12-29 | 2013-04-11 | Emergent Product Development Seattle, Llc | RON Binding Constructs and Methods of Use Thereof |
| AR103268A1 (es) * | 2014-12-23 | 2017-04-26 | Bristol Myers Squibb Co | Anticuerpos contra tigit |
| IL290457B2 (en) * | 2015-12-30 | 2025-02-01 | Kodiak Sciences Inc | Antibodies and their conjugates |
| RU2693661C2 (ru) | 2016-03-04 | 2019-07-03 | Сычуань Келунь-Байотек Байофармасьютикал Ко., Лтд. | Антитело против pdl-1, его фармацевтическая композиция и применение |
| EP3493845A4 (en) * | 2016-08-03 | 2020-04-15 | The Board of Trustees of the Leland Stanford Junior University | INTERRUPTION OF FC RECEPTOR USE ON MACROPHAGES TO IMPROVE THE EFFECTIVENESS OF ANTI-SIRPALPHA ANTIBODY THERAPY |
| WO2018035710A1 (en) * | 2016-08-23 | 2018-03-01 | Akeso Biopharma, Inc. | Anti-ctla4 antibodies |
| CN106977602B (zh) * | 2016-08-23 | 2018-09-25 | 中山康方生物医药有限公司 | 一种抗pd1单克隆抗体、其药物组合物及其用途 |
| CN106967172B (zh) * | 2016-08-23 | 2019-01-08 | 康方药业有限公司 | 抗ctla4-抗pd-1 双功能抗体、其药物组合物及其用途 |
| CN110325549B (zh) * | 2016-12-09 | 2024-03-08 | 艾利妥 | 抗SIRPα抗体及其使用方法 |
| CN106699891B (zh) * | 2017-01-25 | 2019-04-09 | 北京天广实生物技术股份有限公司 | 一种抗pd-l1抗体、其药物组合物及其用途 |
| US20200199247A1 (en) * | 2017-06-07 | 2020-06-25 | Silverback Therapeutics, Inc. | Antibody conjugates of immune-modulatory compounds and uses thereof |
| CN109762068A (zh) * | 2018-08-09 | 2019-05-17 | 源道隆(苏州)医学科技有限公司 | 一种可靶向ctla4和pd-1的单基因双特异性抗体及其应用 |
| EP4008730A4 (en) * | 2019-08-02 | 2023-09-06 | Akeso Pharmaceuticals, Inc. | BISPECIFIC ANTI-CTLA4-ANTI-PD-1 ANTIBODY AND ITS USES |
-
2020
- 2020-07-31 EP EP20850855.6A patent/EP4008730A4/en active Pending
- 2020-07-31 CA CA3146780A patent/CA3146780A1/en active Pending
- 2020-07-31 IL IL321822A patent/IL321822A/en unknown
- 2020-07-31 MX MX2022001321A patent/MX2022001321A/es unknown
- 2020-07-31 CN CN202610888509.7A patent/CN122502501A/zh active Pending
- 2020-07-31 CN CN202010757322.6A patent/CN112300286A/zh active Pending
- 2020-07-31 US US17/630,467 patent/US20220275089A1/en active Pending
- 2020-07-31 PH PH1/2022/550243A patent/PH12022550243A1/en unknown
- 2020-07-31 JP JP2022506483A patent/JP7655896B2/ja active Active
- 2020-07-31 IL IL290255A patent/IL290255B2/en unknown
- 2020-07-31 WO PCT/CN2020/106309 patent/WO2021023117A1/zh not_active Ceased
- 2020-07-31 KR KR1020227006972A patent/KR20220053578A/ko active Pending
- 2020-07-31 AU AU2020325350A patent/AU2020325350A1/en active Pending
- 2020-07-31 BR BR112022002013A patent/BR112022002013A2/pt unknown
-
2025
- 2025-03-21 JP JP2025047199A patent/JP2025102836A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US12331118B2 (en) | Humanized anti-human-PD-1 antibody and methods of using them for cancer treatment | |
| US11202828B2 (en) | Therapeutic SIRP-α antibodies | |
| JP2025102836A5 (cg-RX-API-DMAC7.html) | ||
| IL293241A (en) | Bispecific antibody, anti-1-pd, anti-vegfa, pharmaceutical preparation containing it and its use | |
| CA3058477A1 (en) | Multispecific polypeptide constructs having constrained cd3 binding and methods of using the same | |
| JP2023522730A5 (cg-RX-API-DMAC7.html) | ||
| JP2024509018A5 (cg-RX-API-DMAC7.html) | ||
| JP2024515396A5 (cg-RX-API-DMAC7.html) | ||
| EP4324854A1 (en) | Use of antibody in anti-tumor treatment | |
| JP2025511002A (ja) | 活性化可能な二重特異性抗cd3および抗pd-l1タンパク質ならびにその使用 | |
| KR20220143904A (ko) | 사람 4-1bb 항진제 항체 및 이의 사용 방법 | |
| TH2201000670A (th) | แอนติบอดีชนิดไบสเปซิฟิกสารต้าน ctla4/สารต้าน pd-1 และการใช้ของสิ่งเหล่านั้น | |
| HK40121654A (zh) | 抗体在抗肿瘤治疗中的用途 | |
| TH2201000583A (th) | แอนติ-pd-1 แอนติบอดีและการใช้สารดังกล่าวทางเภสัชกรรม | |
| HK40114665A (en) | Pharmaceutical combination comprising an anti-ctla4-anti-pd-1 bispecific antibody and use thereof | |
| AU2024232344A1 (en) | Pharmaceutical composition comprising anti-ctla4-anti-pd-1 bispecific antibody and use thereof | |
| CA3285164A1 (en) | Pharmaceutical composition comprising anti-ctla4-anti-pd-1 bispecific antibody and use thereof | |
| HK40102352A (en) | Humanized anti-human-pd-1 antibody | |
| CN118767127A (zh) | 抗ctla4-抗pd-1双特异性抗体的医药用途 | |
| HK40101066A (en) | Use of antibody in anti-tumor treatment | |
| HK40060816B (en) | Humanized anti-human-pd-1 antibody | |
| HK40060816A (en) | Humanized anti-human-pd-1 antibody |